EverSource Wealth Advisors LLC Has $172,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

EverSource Wealth Advisors LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 310 shares of the company’s stock after buying an additional 51 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $172,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Patron Partners LLC increased its holdings in IDEXX Laboratories by 2.7% in the fourth quarter. Patron Partners LLC now owns 765 shares of the company’s stock valued at $425,000 after purchasing an additional 20 shares during the last quarter. NewEdge Wealth LLC grew its holdings in IDEXX Laboratories by 3.1% during the fourth quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock valued at $366,000 after purchasing an additional 20 shares during the period. Manchester Capital Management LLC raised its holdings in IDEXX Laboratories by 11.9% in the fourth quarter. Manchester Capital Management LLC now owns 188 shares of the company’s stock worth $104,000 after purchasing an additional 20 shares during the period. Phoenix Holdings Ltd. raised its stake in IDEXX Laboratories by 2.8% during the 3rd quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock worth $338,000 after buying an additional 21 shares during the period. Finally, BluePath Capital Management LLC lifted its holdings in IDEXX Laboratories by 1.8% during the fourth quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock worth $663,000 after acquiring an additional 21 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX traded up $0.40 during trading on Friday, hitting $516.50. 267,200 shares of the company traded hands, compared to its average volume of 546,767. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock’s fifty day moving average is $509.96 and its 200 day moving average is $522.68. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The firm has a market cap of $42.66 billion, a P/E ratio of 50.00, a price-to-earnings-growth ratio of 4.21 and a beta of 1.27.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. The business had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of research reports. JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Morgan Stanley cut their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, Barclays cut their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $580.38.

Insider Activity

In related news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the sale, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.11% of the stock is currently owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.